Exosome Hair Treatment in Dubai
Plant-derived regenerative therapy for hair thinning with the evidence, the limits, and the price stated up front.
Book Appointment
Home / Treatment / Exosomes Hair Therapy New
Plant-derived regenerative therapy for hair thinning with the evidence, the limits, and the price stated up front.
Book Appointment
Exosome hair treatment is a non-surgical regenerative procedure in which nanoscale extracellular vesicles typically 30–150 nanometres across are delivered into the scalp to signal hair follicles toward a more active growth state.
Exosomes are not cells and not a drug. They are signalling packages. Each vesicle carries proteins, growth factors and microRNAs that cells normally use to communicate instructions to one another. Delivered into the scalp, that cargo may prompt dermal papilla cells to proliferate, support local blood vessel formation, and modulate the inflammation that surrounds miniaturising follicles.
The treatment is designed for people with thinning hair, not bald scalps. Where a follicle has completely scarred over or died, no regenerative signal will restore it. This is the single most important thing to understand before booking.
Most clinic pages in Dubai say "stem cell-derived exosomes" and stop there. That phrase covers products with completely different origins, and patients deserve to know which one is going into their scalp.
Exosome products used in aesthetics come from broadly two categories:
|
Source category |
Typical origin |
Considerations |
|---|---|---|
|
Human / mammalian MSC-derived |
Adipose tissue, placenta, umbilical cord, foreskin-derived mesenchymal stromal cells |
Carries most of the published clinical trial data. Raises donor-tissue, religious and regulatory questions for many patients. |
|
Plant-derived |
Plant callus cultures — e.g. Rosa damascena (Damask rose) stem cells |
Non-animal and non-human origin. Fewer donor-sourcing concerns. Smaller but growing clinical dataset. |
At Halcyon we use ASCE+ (ExoCoBio, South Korea), which is a plant-derived system built on Rosa damascena rose stem cell extracellular vesicles. No human donor tissue is involved.
For many of our patients in Dubai this is the deciding factor, and it is rarely discussed openly. If the origin of an injected biological product matters to you — on religious, ethical or personal grounds — you are entitled to ask any clinic for the product name, the manufacturer, and the source material in writing before you consent. We provide it as standard.
ExoCoBio manufactures ASCE+ under ISO 13485 quality management using its ExoSCRT isolation technology. A published clinical letter by Lueangarun and colleagues in the Journal of Cosmetic Dermatology specifically examined rose stem cell-derived exosomes for hair regeneration in androgenetic alopecia (Lueangarun, Cho, & Tempark, 2024).
Regulatory status, stated plainly: ASCE+ is registered as a cosmeceutical in South Korea. It is not approved by the US FDA as a drug or biologic — and neither is any other exosome product anywhere in the world. As of 2026 there are zero FDA-approved exosome products for any therapeutic use (U.S. Food and Drug Administration, 2020). Any Dubai clinic describing its exosome product as "FDA-approved" is describing something that does not exist. Devices used alongside the treatment, such as microneedling pens, may carry their own separate approvals — that is a different claim.
Visible hair regrowth and thickening.
30 minutes.
Local anaesthetic.
4-6 Sessions, 3-6 weeks Apart.
Exosome therapy for hair loss is genuinely promising and genuinely early. Here is the state of the evidence as of 2026, with sources, so you can weigh it yourself.
What has been measured in published studies
What the evidence does not yet establish and no clinic should imply otherwise
A 2025 systematic review summarising the field concluded that exosome therapy shows promising short-term hair regrowth outcomes with a favourable safety profile, while describing the modality as an exciting but still experimental tool in alopecia management pending larger standardised trials.
That is an honest summary. If you want a treatment with decades of large-scale data behind it, topical minoxidil is that treatment, and we will tell you so in consultation.
Exosomes influence hair growth through several parallel routes rather than one pharmacological switch
This is meaningfully different from minoxidil, which prolongs the anagen phase by opening potassium channels and increasing scalp blood flow without delivering growth-factor signalling, and which requires indefinite daily use to maintain any benefit.
Exosome hair treatment may be appropriate if you
It is generally not the right treatment if you are looking to restore a fully bald area, or if your hair loss is driven by an untreated underlying condition in which case that condition is the priority.
Exosome hair treatment is not suitable for everyone. Do not proceed, and disclose the following at consultation, if any apply
Reported effects are generally mild and transient: injection-site redness, swelling, tenderness, pinpoint bleeding, and occasionally mild headache or scalp tightness. In published clinical series these occurred at rates close to placebo and resolved without intervention. Because exosome products are not standardised across manufacturers, long-term safety data remains limited a point we raise with every patient rather than leave in a footnote.
Contact the clinic promptly if you develop spreading redness, significant swelling, discharge, fever, or pain that worsens rather than settles after 48 hours.
|
Exosome therapy |
PRP |
Topical minoxidil |
|
|---|---|---|---|
|
Source |
Manufactured vesicles (plant-derived at Halcyon) |
Your own blood |
Pharmaceutical |
|
Blood draw needed |
No |
Yes |
No |
|
Consistency between patients |
Standardised per batch |
Varies with your platelet count, age, health |
Standardised |
|
Evidence base |
Early — small trials, short follow-up |
Larger, more established, mixed results in women |
Largest — decades of data |
|
Regulatory status |
No FDA-approved exosome product exists |
Autologous, widely used |
FDA-approved for AGA |
|
Typical course |
4–6 sessions, 3–6 weeks apart |
3–6 sessions monthly |
Twice daily, indefinitely |
|
Maintenance |
Periodic; long-term need not yet defined |
Benefits may decline after 12–16 months without top-ups |
Discontinuation leads to relapse |
|
Cost per session (Dubai) |
Higher |
Moderate |
Low |
Published comparative data suggests exosome therapy produces hair regrowth outcomes broadly comparable to PRP, with the caveat that the exosome trials are small and short (Darwish et al., 2025). PRP has more robust long-term follow-up. In several studies, combination approaches outperformed any single treatment.
We do not claim exosome therapy is "better than PRP." The honest position is that they are different tools suiting different patients, and the published evidence does not support a blanket superiority claim in either direction. If PRP or mesotherapy is a better fit for your case or if a combination is that is what we will recommend. Our PRP hair treatment page covers that option in detail.
AED 2,400 per session at Halcyon Aesthetics Clinic, Jumeirah.
Because a typical course runs 4–6 sessions, plan realistically for AED 9,600–14,400 for a full initial course, plus any maintenance. We publish this because a per-session figure without the course context is how patients end up surprised, and we would rather you budget accurately than start a protocol you cannot finish. An incomplete course is unlikely to deliver a meaningful result.
Across Dubai, advertised exosome hair pricing ranges from under AED 1,000 to over AED 3,000 per session. Very low headline prices usually reflect a lower particle concentration, a partial-scalp application, or an introductory session that is not representative of course pricing. When comparing quotes, ask three questions: which product and manufacturer, how many particles per session, and how many sessions are in the quoted course.
Real results, real patients. See the difference our treatments make
Before
After
Before
After
Before
After
Exosome hair treatment delivers nanoscale extracellular vesicles into the scalp to signal hair follicles toward more active growth. The vesicles carry growth factors, proteins and microRNAs. It is a non-surgical procedure typically performed over a course of 4–6 sessions, and it works on thinning hair where live follicles remain not on fully bald or scarred scalp.
No. As of 2026 there are no FDA-approved exosome products for any therapeutic use anywhere. Some clinics advertise "FDA-approved exosomes" this is inaccurate. Devices used during the procedure, such as microneedling pens, may hold separate device approvals, which is a different thing from the exosome product itself being approved. ASCE+ is registered as a cosmeceutical in South Korea.
It depends entirely on the clinic and product. Many exosome products used in aesthetics are derived from human or animal mesenchymal stromal cells adipose, placental, umbilical cord or foreskin-derived. The ASCE+ system we use at Halcyon is plant-derived, built on Rosa damascena rose stem cell extracellular vesicles. No human donor tissue is involved. If sourcing matters to you, ask any clinic to state the product name, manufacturer and source material in writing before you consent.
In published clinical studies the short-term safety profile has been favourable, with transient injection-site redness or swelling occurring at rates similar to placebo and no serious adverse events reported. However, long-term safety data is limited and exosome products are not standardised between manufacturers. Suitability depends on your individual medical history see the contraindications section above, and discuss any medical condition or medication with a qualified practitioner before proceeding.
The published evidence does not support a blanket claim that either is better. Comparative reviews describe exosome outcomes as broadly comparable to PRP, while noting exosome trials are small and short-term whereas PRP has longer follow-up data. Exosome therapy avoids a blood draw and offers batch-to-batch consistency; PRP uses your own biology and has a more established track record. The right choice depends on your diagnosis, and combination protocols sometimes outperform either alone.
Honestly: this is not yet established. Published exosome trials have follow-up periods of roughly 6 to 12 weeks, so multi-year durability data does not exist. In clinical practice, maintenance sessions are typically discussed at 6–12 month intervals depending on individual response and the underlying cause of hair loss. Any clinic guaranteeing results "for years" is going beyond the evidence.
Reduced shedding is often the first change patients report, commonly around 4–8 weeks. Visible density change is generally assessed at 3–4 months, because hair grows on a slow biological cycle and no treatment shortcuts it. Results vary by individual, by the cause and stage of hair loss, and by whether the full course is completed.
Topical local anaesthetic is applied before the procedure, and most patients describe the sensation as mild pressure or tingling rather than pain. Some scalp tenderness for around 24 hours afterwards is normal.
No. We do not treat pregnant or breastfeeding patients with exosome therapy. There is no safety data in this population, and we will not proceed on the basis that no evidence of harm has been reported. Post-partum hair shedding is also very often self-resolving we will discuss appropriate timing and alternatives with you.
Microblading helps restore the appearance of lost eyebrow hair due to thinning or shedding.
